

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI)
Berufsverband Deutscher Anästhesisten e.V. (BDA)
Deutsche Akademie für Anästhesiologische Fortbildung e.V. (DAAF)
Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI)



Pompe disease

Porphyrria

orphan**a**nesthesia

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 2 | 2018

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patienten mit seltenen Erkrankungen. Damit will Orphan Anesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesisten damit keine Erfahrungen gesammelt haben, so dass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem ein Anästhesist sowie ein weiterer Krankheitsexperte (z.B. Pädiater oder Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, so dass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a common project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

A survey of until now in A&I published guidelines can be found on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu



Deutsche Gesellschaft für Anästhesiologie & Intensivmedizin

www.dgai.de



ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

www.ai-online.info

Projektleitung

Prof. Dr. Tino Münster, MHBA
Geschäftsführender Oberarzt
Facharzt für Anästhesie,
Spezielle Schmerztherapie,
Notfallmedizin
Anästhesiologische Klinik
Friedrich-Alexander-Universität
Erlangen-Nürnberg
Krankenhausstraße 12
91054 Erlangen, Deutschland
Tel.: 09131 8542441
Fax: 09131 8536147
E-Mail: muenster@kfa.imed.uni-erlangen.de

orphananesthesia

Anaesthesia recommendations for patients suffering from **Porphyria**

Disease name: Porphyria

ICD 10: E80.0, E80.1, E80.2

Synonyms: ALA dehydratase deficiency porphyria (ADP), acute intermittent porphyria (AIP), congenital erythropoietic porphyria (CEP), erythropoietic protoporphyria (EPP), hereditary coproporphyria (HCP) porphyria cutanea (PCT), plumboporphyria (PP), variegate porphyria (VP), X-linked protoporphyria (XLP)

Porphyrias are a group of metabolic disorders, mainly inherited, in which there are defects in the heme biosynthetic pathway that may lead secondarily to overproduction of one or more heme precursors. Heme is essential for transport of oxygen from the lungs to tissues and removal of carbon dioxide from tissues to the lungs for excretion (haemoglobin) and biotransformation (respiratory chain, cytochromes P-450, and other heme-containing enzymes). Eight different enzymes are involved in the biosynthesis of heme. The activity of the entire pathway is chiefly related to end-product repression of activity of the first and normally rate-controlling enzyme of the pathway, namely 5-aminolevulinic acid (ALA) synthase. Partial deficiency of heme leads to up-regulation of ALA synthase by several molecular mechanisms, whereas sufficiency or excess of heme leads to down-regulation of ALA synthase through effects on gene transcription, decreased stability of its mRNA, decreases in its transport into mitochondria, and decreases in half-life of the mature mitochondrial for of the synthase.

Medicine in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnostic is wrong

► **Citation:** Rapp HJ: Porphyria. AnästH Intensivmed 2018;59:S26-S40. DOI: 10.19224/ai2018.S026

Disease summary

The enzyme deficiency disorders follow either an autosomal dominant, autosomal recessive or x-linked inheritance except the sporadic PCT. There are eight different forms of porphyria, non-acute and acute forms, depending on the chief site of overproduction of heme precursors. Porphyrins are classically divided into hepatic or erythropoietic types. Another useful classification is according to cardinal clinical manifestations: four of the diseases may give rise to acute attacks with neuro-visceral manifestations [the acute or inducible porphyrias AIP, VP, HCP, PP], and these are an issue concerning anaesthesia. Other forms cause cutaneous manifestations. However, for two of the diseases, namely, hereditary coproporphyria and variegate porphyria, patients may have both neuro-visceral and cutaneous manifestations. The non-acute porphyrias do not exhibit the acute symptoms of neurological disorders, abdominal pain, and electrolyte abnormalities, and in particular they are not triggered by anaesthetic agents or any drugs. Therefore they do present a serious perioperative risk.

Incidence: acute porphyric attacks hardly ever occur before puberty. They are mainly disease of women in their child-bearing years [Ages 18-50 years]. In most countries, acute intermittent porphyria is the most common and most severe form of acute porphyria, with symptomatic disease occurring in 1:10,000 to 1:20,000. In patients with psychiatric disorders, the prevalence may be higher, perhaps as high as 1:500. The prevalence of genetic defects in the hydroxymethyl bilane synthase (hmbcs) gene [also known as porphobilinogen deaminase] is far higher, about 1/1,600 persons in Western Europe, emphasizing the importance of other genetic or acquired factors in pathogenesis. Both, symptomatic and asymptomatic heterozygotes, have 50 percent or greater of porphobilinogen deaminase activity in the majority of patients; a total deficiency is not reconcilable with life. 90 percent of individuals with the deficiency exhibit no clinical signs. Hormonal and nutritional factors, as well as pharmacologic agents (induction of ALA (amino levulinic acid) -synthetase) may exacerbate the disorder. Initiating factors for an overproduction are infections, starvation, alcohol, induction of hepatic CYP 450 by drugs (such as barbiturates), pregnancy, hormones.

Other symptoms: Acute attacks occur after puberty, commonly in females, cause abdominal pain, obstipation, nausea, autonomic instability with hypertension, tachycardia, neuropathy, muscle weakness, paraesthesia, neuropsychiatric abnormalities, depression, electrolyte abnormalities, haemolytic anaemia, hepatic failure, or cirrhosis.

Typical surgery

None.

Because patients typically present with severe abdominal pain, there is increased likelihood that patients with acute porphyrias will be subjected to exploratory laparotomies, appendectomies, and/or cholecystectomies. Typically, at surgery there is no evidence of acute appendicitis or cholecystitis, and such surgeries do not prevent recurrence of symptoms.

Type of anaesthesia

General or regional anaesthesia, both are possible under avoidance of initiating factors and unsafe or unclear medication.

Necessary additional diagnostic procedures (preoperative)

- Consultation with an experienced anaesthesiologist in advance to better plan surgery and anaesthesia management
- Consultation with a physician with special expertise in evaluation and management of the porphyrias is desirable
- Consultation with a neurologist if there are neurologic signs
- Urine sampling for preliminary staging of porphyria precursors
- No stress
- No starvation; maintenance of adequate intake of carbohydrates and energy [kCal].

Particular preparation for airway management

None, only in special cases with known or suspected airway abnormalities.

Particular preparation for transfusion or administration of blood products

None.

Particular preparation for anticoagulation

None.

Particular precautions for positioning, transport or mobilisation

- No UV light source
- Soft positioning, gel cushion.

Probable interaction between anaesthetic agents and patient's long term medication

No fasting, no corticosteroids for initial PONV prophylaxis, induction medication: propofol (avoid barbiturates!), preoperative glucose supplementation.

Anaesthesiologic procedure

- Preoperative preparation together with experienced anaesthesiologist, surgeon or other physician with expertise in porphyria management
- (Urine sampling and laboratory values for preoperative staging of precursors)
- Maintenance of fluid and carbohydrates (300g/day), no fasting
- Premedication with midazolam if considered necessary
- PONV prophylaxis: no corticosteroids, use Droperidol
- Preparation in a stress-free setting with soft positioning
- Induction of anaesthesia using Morphine, Propofol and Vecuronium for relaxation, maintenance using Desflurane
- Reversal of muscle relaxation if necessary with Atropine, Neostigmine
- Postoperative analgesia, Morphine, Ibuprofen or regional anaesthesia technique using Bupivacaine.

Particular or additional monitoring

- Provide perioperative care, presurgical admission for iv hydration with glucose containing fluids (300 g/day) to down-regulate ALA synthase-1
- Intensify clinical monitoring (temperature, nausea, vomiting, diarrhoea, seizures psychotic signs, peripheral neuropathy)
- Laboratory (serum sodium, colour of urine, 5-amino-levulinic acid, porphobilinogen)
- Provide care on intermediate care or intensive care unit if necessary.

Possible complications

The disease may be disabling, but in most cases it does not lead to a fatal outcome. Late diagnosis, however, and delayed onset of treatment may result in life-threatening complications like renal insufficiency, liver cirrhosis, or in rare cases a lethal course.

A common symptom is abdominal pain. Together with symptoms like ileus, distention, constipation or diarrhoea, nausea, vomiting it may be often misinterpreted as acute abdomen.

Muscle weakness, sensory loss and peripheral neuropathy, due to axonal degeneration of neurons, may be seen. However it is not common in all acute attacks; progression up to respiratory or bulbar paralysis and death may occur if proper diagnosis and treatment are delayed.

Seizures are not uncommon due to hyponatremia, hypomagnesemia, or neurologic effects and treatment may be challenging because of exacerbation by most commonly used anti-convulsants (barbiturates, hydantoins, lamotrigine, or other potent inducers of cytochromes P-450). It appears that levetiracetam and vigabatrin are safe for use in treatment and prophylaxis of seizures complicating the acute porphyrias.

Postoperative care

- Provide sufficient perioperative care in the recovery room for all patients, and provide additional care on intermediate care or intensive care unit in extensive surgery
- Continue iv. hydration with glucose containing fluids (300 g/day) to suppress synthesis of ALA synthase-1
- Provide heme intravenously (3mg/kg BW per day for three-five days) if needed (Treatment of choice for acute porphyric attacks)
- Intensify monitoring for: hypothermia, psychotic symptoms, nausea, vomiting, diarrhoea, seizures)
- Laboratory (control serum sodium, magnesium levels, colour of urine, 5-amino-levulinic acid, porphobilinogen).

Information about emergency-like situations / Differential diagnostics

caused by the illness to give a tool to distinguish between a side effect of the anaesthetic procedure and a manifestation of the disease

In case of symptoms like:

- unclear convulsions, seizures: start acute crisis treatment with glucose and heme, in the form of heme arginate (Normosang) or hydroxy heme (Panhematin, Recordati)

In cases with symptoms like: (Be alert, these might be first signs of an acute attack. Consider relation to porphyria and start treatment)

- Vertigo
- Acute cephalic pain
- Muscular weakness
- Syncope
- Systemic arterial hypertension, hypertensive crisis

- Acute renal insufficiency
- Hepatic insufficiency
- Acute trouble of the vision
- Acute severe pain
- Acute infection
- Pyrexia
- Acute abdominal pain
- Vomiting; severe constipation (obstipation).

Ambulatory anaesthesia

It is better not to perform ambulatory anaesthesia.

Obstetrical anaesthesia

Consultation with experienced anaesthesiologist early in pregnancy to better plan surgery and procedures, examination, laboratory testing.

Determination of anaesthesia type.

During delivery: Sufficient pain therapy, early insertion of epidural catheter.

Literature and internet links

1. Bonkovsky HL, Maddukuri V, Yazici C, et al. Acute porphyrias in the USA: Features of 108 subjects from porphyria consortium. *Am J Med* 2014. Pii:S0002-9343(14)00577-4. doi: 10.1016/j.amjmed. 2014. 06.036
2. Bonkovsky HL, Hou W, Li T, Guo J-T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. In: Wolkoff A, Lu S, and Omary B (Eds). *Comprehensive Physiology* 2013,3:365-401, [The American Physiological Society, Bethesda, MD, Wiley and Co] [PMID 23720291]
3. Desnick RJ, Balwani M. Chapter 358, The Porphyrias pp 3167-3181. In: Longo, et al. *Harrison's Principles of Internal Medicine*, 18th ed. McGraw Hill
4. Dhillon A, Steadman RH. Chapter 5 Liver Diseases. In: Fleischer LA, *Anesthesia and Uncommon Diseases*, 6th ed. Elsevier
5. Dover SB, Plenderleith L, Moore MR, McColl KEL. Safety of general anaesthesia and surgery in acute hepatic porphyria. *Gut* 1994;35:1112-1115
6. Hahn M, Gildemeister OS, Krauss GL, Pepe JA, Lambrecht RW, Donohue S, Bonkovsky HL. Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells-potential implications for patients with acute porphyria. *Neurology* 1997;49: 97-106
7. Kunitz O, Frank J. Anästhesiologisches Management bei Patienten mit akuten Porphyrien. *Anaesthesist* 2001;50:957-969
8. Lambrecht RW, Gildemeister OS, Pepe JA, Tortorelli KD, Williams A, Bonkovsky HL. Effects of antidepressants and benzodiazepine-type anxiolytic agents on hepatic porphyrin accumulation in primary cultures of chick embryo liver cells. *J Pharmacol Exp Ther* 1999;29:1150-1155
9. Lambrecht RW, Gildemeister OS, Williams A, Pepe JA, Tortorelli KD, Bonkovsky HL. Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation. *Biochem Pharmacol* 1999;58:887-896
10. Merkblatt Referenzlabor Stadtspital Triemli Zürich
pdf: http://www.stadt-zuerich.ch/triemli/de/index/kliniken_institute/zentrallabor/epp_diagnostik.html

Last date of modification: December 2014

This guideline has been prepared by:

Author

Hans-Juergen Rapp, Anaesthesiologist, Buergerhospital Frankfurt/Main, Germany
hj.rapp@buergerhospital-ffm.de

Peer revision 1

Mike James, Anaesthesiologist, University of Cape Town, South Africa
mike.james@uct.ac.za

Peer revision 2

Herbert Bonkovsky, Department of Medicine and The Liver-Biliary-Pancreatic Center,
Carolinas Medical Center, Charlotte, North Carolina, USA
herbert.bonkovsky@carolinashealthcare.org

Amendment 1

Prescription of drugs

Several lists of drugs have been developed over the past 40 years or so. All are based chiefly upon expert opinion and upon basic knowledge of the pharmacology of the drugs, such as whether drugs are known to be inducers of cytochromes P-450.

The main drugs lists are those of The Swedish Porphyria Centre, NAPOS, the European Porphyria Initiative, the American Porphyria Foundation, and the South African/University of Capetown. These lists have similar methods of classifying drugs and do not always agree.

For example, The Scandinavian [NAPOS] scheme uses the following categories:

- Not porphyrinogenic (NP)
- Probably not porphyrinogenic (PNP)
- Possibly porphyrinogenic (PSP),
- Probably porphyrinogenic (PRP)
- Porphyrinogenic (P)
- Not yet classified (NC)

Select drugs accordingly: NP, PNP, PSP, PRP, P with first choice classified as NP or PNP.

Before prescribing any drug labeled PSP, PRP or P, it has to be justified:

- is there a real need for the drug?
- is there no safer alternative available?
- is there a benefit from using the drug of choice?
- is there a risk of provoking an acute attack and the consequences?
- is the risk considered justified by the expected benefit ?

Amendment 2

List of drugs

Before prescribing any drug labeled PSP, PRP or P, it has to be justified:

- is there a real need for the drug?
- is there no safer alternative available?
- is there a benefit from using the drug of choice?
- is there a risk of provoking an acute attack and the consequences?
- is the risk considered justified by the expected benefit?

List of drugs

A: Note: List based on Fleischer IE, Anesthesia and uncommon diseases

Considered as safe:

i.v. anaesthetics: *Lorazepam, Midazolam, Propofol*
Volatile anaesthetics: *Desflurane, Nitrous oxide*
Opiates: *Morphine; meperidine*
Muscle relaxants: *Succinylcholine, Vecuronium*
Local anaesthetics: *Bupivacaine, Procaine*
Maintaining and termination anaesthesia: *Atenolol, Atropine, Droperidol, Labetalol, Neostigmine*

Considered unsafe:

i.v. anaesthetics: *Barbiturates, Etomidate*
Volatile anaesthetics: *Enflurane*
Opiates: *none*
Muscle relaxants: *none*
Local anaesthetics: *none*
Maintaining and termination anaesthesia: *Gucocorticoids, Hydralazine*

Considered unclear:

i.v. anaesthetics: *Diazepam, Ketamine*
Volatile anaesthetics: *Halothane, Isoflurane*
Opiates: *Alfentanil, Sufentanil*
Muscle relaxants: *Atracurium, Pancuronium*
Local anaesthetics: *Lidocaine*
Maintaining and termination anaesthesia: *none*

B: Note: based on list in "Patient's and Doctor's Guide to Medication in Acute Porphyria," Swedish Porphyria Association and Porphyria Centre Sweden. Also see the website Drug Database for Acute Porphyrias (www.drugs-porphyria.com) for a searchable list of safe and unsafe drugs.

Documented Porphyrogenic:

Carbamazepine, Carisoprodol, Chloramphenicol, Clindamycin
Dextropropoxyphene, Dihydralazine, Dihydroergotamine, Drospirenone + estrogen Dydrogesterone
Etonogestrel
Fosphenytoin sodium
Hydralazine, Hydroxyzine,
Indinavir
Ketamine, Ketoconazole
Lidocaine, Lynestrenol, Lynestrenol + estrogen,
Mecillinam, Medroxyprogesterone, Megestrol, Methylergometrine, Methyldopa Mifepristone,
Nicotinic Acid/meclozine/hydroxyzine, Nitrofurantoin, Norethisterone, Norgestimate + estrogen
Orphenadrine,
Phenobarbital, Phenytoin, Pivampicillin, Pivmecillinam, Primidone,
Rifampicin, Ritonavir, Spironolactone, Sulfadiazine +
Trimethoprim, Tamoxifen, Testosterone, injection Thiopental, Trimethoprim,
Valproic acid, Venlafaxine, Vinblastine, Vincristine, Vindesine, Vinorelbine
Xylometazoline,
Zaleplon, Ziprasidone, Zolmitriptan, Zolpidem, Zuclopenthixol

Probably porphyrogenic

Altretamine, Aminophylline, Amiodarone, Amitriptyline, Amlodipine, Amprenavir, Aprepitant,
Atorvastatin, Azathioprine
Bosentan, Bromocriptine, Buspirone, Busulfan, Butylscopolamine
Cabergoline, Ceftriaxone +, Cerivastatin, Cetirizine, Cholinetheophyllinate, Clarithromycin, Clemastine,
Clonidine, Cyclizine, Cyproterone
Danazol, Delavirdine, Desogestrel + estrogen, Diazepam, Dienogest + estrogen, Dydrogesterone,
Diclofenac, Diltiazem, Diphenhydramine, Disopyramide, Disulfiram, Drospirenone +,

Estrogen, Ergoloidmesylate, Erythromycin, Estramustine, Ethosuximide, Etoposide, Exemestane

Felbamate, Felodipine, Fluconazole, Flunitrazepam, FLuvastatin

Glibenclamide

Halothane, Hyoscyamine

Ifosfamide, Imipramine, Irinotecan, Isoniazid, Isradipine, Itraconazole

Lamivudine +Zidovudine, Lansoprazole, Lercanidipine, Levonorgestrel, Lidocaine, Lopinavir, Lutropin alfa, Lymecline

Meclozine, Medroxyprogesterone + Estrogen, Metoclopramide, Metronidazole, Metyrapone, Moxonidine

Nandrolone, Nefazodone, Nelfinavir, Nevirapine , Nifedipine, Nimodipine, Nitrazepam, Norethisterone, Nortriptyline

Oxcarbazepine, Oxytetracycline

Paclitaxel, Paroxetine, Phenazone + caffeine, Pioglitazone, Probenecid, Progesterone vaginal Gel

Quinidine

Rabeprazole, Raloxifene, Rifabutin, Riluzole, Risperidone, Rosiglitazone

Saquinavir, Selegiline, Simvastatin, Sulfasalazine

Telithromycin, Terbinafine, Terfenadine, Testosterone Transdermal patch, Tetracycline, Theophylline, Thiamazole, Tibolone, Ticlopidine, Tinidazole, Thiotepa, Topiramate, Topotecan, Toremifene, Tramadol, Trimegestone + Estrogen

Verapamil, Voriconazole

Zidovudine/azt

Possibly Porphyrinogenic

Aceclofenac, Acitretin, Acrivastine, Alfuzosin, Anastrozole, Auranofin, Azelastine

Benzotropine, Benzydamine, Betaxolol, Bicalutamide, Biperiden, Bupropion,

Carvedilol, Chlorambucil, Chlorcyclizine + Guaifenesin, Chloroquine, Chlorprothixene, Chlorzoxazone, Chorionic Gonadotrophin, Ciclosporin, Cisapride, Citalopram, Clomethiazole, Clomiphene, Clomipramine, Clopidogrel, Clotrimazole, Cortisone, Cyclandelate, Cyclophosphamide, Cyproheptadine,

Dacarbazine, Daunorubicin, Desogestrel, Dichlorobenzyl Alcohol, Dithranol, Docetaxel, Donepezil, Doxycycline,

Ebastine, Econazole, Efavirenz, Escitalopram, Esomeprazole, Estradiol/tablets, Estriol/tablets, Estrio/vainal crème, tablet, Estrogen Conjugate,

Fentanyl, Finasteride, Flecainide, Flucloxacillin, Fluoxetine, Flupentixol, Flutamide, Fluvoxamine, Follitropin alfa

Beta Galantamine, Glimepiride, Glipizide, Gonadorelin, Gramicidin, Guaifenesin

Hydrocortisone, Hydroxycarbamide, Hydroxychloroquine,

Ibutilide, Imatinib, Indomethacin,

Ketobemidone + Ddba, Ketoconazole, Ketorolac,

Lamotrigine, Letrozole, Levodopa + Benserazide, Levonorgestrel Intrauterine, Levosimendan, Lidocaine, Linezolid, Lofepamine, Lomustine,

Malathion, Maprotiline, Mebendazole, Mefloquine, Melperone, Melphalan, Mepenzolate, Mepivacaine, Mercaptopurine, Methadone, Methylprednisolone, Methixene, Metolazone, Metronidazole, Mexiletine, Mianserin, Midazolam, Minoxidil, Mirtazapine, Mitomycin, Mitoxantrone, Moclobemide, Montelukast, Morphine + Scopolamine, Multivitamins, Mupirocin,

Nabumetone, Nafarelin, Naltrexone Nateglinide, Nilutamide, Noscapine,

Omeprazole, Oxybutynin, Oxycodone,

Pantoprazole, Papaverine, Parecoxib, Pentifylline, Pentoxyverine, Phenylpropanolamine + Cinnarizine, Pizotifen, Polidocanol, Polyestradiol, Phosphate, Potassium canrenoate, Pravastatin, Prednisolone, Prilocaine, Proguanil, Propafenone, Pseudoephedrine + Dexbrompheniramine,

Quillaia extract, Quinagolide, Quinine, Quinupristin + Dalfopristin

Reboxetine, Repaglinide, Rizatriptan, Rofecoxib, Ropinirole, Ropivacaine, Roxithromycin,

Sertraline, Sevoflurane, Sibutramine, Sildenafil, Sirolimus, Sodium Aurothiomalate, Sodium oleate + Chlorocymol, Stavudine, Sulindac, Sumatriptan,

Tacrolimus, Tadalafil, Tegafur + uracil, Telmisartan, Thioridazine, Tioguanine, Tolfenamic acid, Tolterodine, Torsemide, Triamcinolone, Trihexyphenidyl, Trimipramine,

Valerian, Venlafaxine, Vinblastine, Vincristine, Vindesine, Vinorelbine,

Xylometazoline,

Zaleplon, Ziprasidone, Zolmitriptan, Zolpidem, Zuclopenthixol

C: Note: Drugs accordingly the „Merkblatt Referenzlabor Stadtspital Triemli“ (Zürich)

Medication in acute porphyrias considered as safe

Indication: medication (trade name)

Allergic reaction:

- Adrenalin, Cetirizin (Zyrtec), Corticosteroide, Cromoglicin acid (Lomudal), Dexchlorpheniramin (Polaramin).

Seizures:

- Clonazepam (Rivotril), Gabapentin (Neurontin), levetiracetam, Vigabatrin (Sabril),
- Coping seizure:: 1 x 10 mg Diazepam (Valium) i.v. (only one simple dose)

Nausea, Vomiting:

- Chlorpromazine (Largactil), Cyclizine (Marzine), Domperidon (Motilium), Droperidol (Dehydrobenzperidol), Scopolamin

Hypertension und Tachycardia:

- ACE-inhibitors: Lisinopril (Corpril, Lisitril, Lisopril, Prinil, Tobicor, Zestril), Enalapril (Acepril, Elpradil, Enalapril, Enatec, Epril, Reniten, Vascor), [Calcium-channel-blocker: contraindication]
- Beta-blockers i.a.: Atenolol (Tenormin), Propranolol (Inderal, Betaprol) [Acute Attack - Combination Beta-Blocker und Chlorpromazine advantageous. Beware of Orthostatic hypotension or excessive beta-blockade], Labetalol (Trandate).

Diuretics:

- Amilorid (Midamor), Bumetamid (Burinex), Furosemid (Lasix), Hydrochlorothiazid (Esidrex)

Infection:

- Penicillines: Amoxicillin, Ampicillin, Benzathinpenicillin, Cloxacillin, Phenoxymethylpenicillin
- Aminoglycosides: Amikacin, Gentamycin, Kanamycin, Netilmycin, Streptomycin, Tobramycin
- Cephalosporines: Cefoxitin, Cefuroxim, Cefotaxim)
- Others: Vancomycin, Augmentin

Heart Disease:

- Atropine (Atropine Dispersa, Skiatropin)
- Digitalisglycosides (Digoxin), Procaine (Pronestyl),
- Glyceryltrinitrate (Nitroglycerin), Isosorbid Dinitrate (Isoket), Isosorbid Monohydrate (Corangin)
- Adrenalin, Dobutamin, Dopamine

Diarrhea, Obstipation, Ileus:

- Loperamide (Immodium), Neostigmin (Prostigmin)

Psychosis, State of Fear and Arousal:

- Chlorpromazine (Largactil), Fluphenazine (Dapotum), Haloperidol (Haldol), Levomepromazine (Nozinan), Perphenazine (Trilafon), Temazepam (Normison), Triazolam (Halcion).

Pain:

- Acetylsalicylic acid (Aspirin, Aspegic), Buprenorphine (Temgesic), Codeine (Paracodin, Codein Knoll, Tricodein Solco), Flurbiprofen (Froben, Ocuflur), Ibuprofen (e.g. Brufen), Indomethacin (z.B. Bonidon, Confortid, Indocid), Morphine, Naproxen (Apranax, Naprosyn, Proxen), Paracetamol (z.B. Dafalgan), Pethidine (Centralgin, Pethidin Amino, Pethidin Streuli),

Sleeplessness:

- Lorazepam (Temesta), Oxazepam (Seresta)

Local Anesthetics:

- Bupivacaine (Carbostesin, Carbostesin-Adrenalin): maximum 10 ml of 5 mg/ml solution, Levobupivacaine (Chirocain): maximum 10 ml of 5 mg/ml solution, Procaine (Syntocain).

Vaccination:

- Influenza-vaccination recommended, all vaccinations are acceptable

Antidepressants:

- Lithium salts, Fluoxetine (Fluctine)

Coughing / Cold:

- Acetylcysteine (Fluimucil), Codeine (Codein, Makatussin), Dextromethorphan (Bexin), Pseudoephedrine (Otrinol)

Miscellaneous

- Anticoagulants (Marcoumar, Heparin, fractioniated Heparin), Corticosteroids ex. Triamzinolon (Kenacort), Dexamethasone (Milicorten), Insulin, Metformin (e.g. Glucophage), Synacthen, Vitamins.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e.V.
Präsident: Prof. Dr.
B. Zwißler, München



BDA

Berufsverband Deutscher
Anästhesisten e.V.
Präsident: Prof. Dr.
G. Geldner, Ludwigsburg



DAAF

Deutsche Akademie
für Anästhesiologische
Fortbildung e.V.
Präsident: Prof. Dr.
F. Wappler, Köln

Schriftleitung

Präsident/in der Herausgeberverbände

Gesamtschriftleiter:

Prof. Dr. Dr. Kai Zacharowski, Frankfurt

Stellvertretender Gesamtschriftleiter:

Prof. Dr. T. Volk, Homburg/Saar

CME-Schriftleiter:

Prof. Dr. H. A. Adams, Trier

Redaktionskomitee

Prof. Dr. G. Beck, Wiesbaden

Dr. iur. E. Biermann, Nürnberg

Prof. Dr. H. Bürkle, Freiburg

Prof. Dr. B. Ellger, Dortmund

Prof. Dr. K. Engelhard, Mainz

Prof. Dr. M. Fischer, Göppingen

Priv.-Doz. Dr. T. Iber, Baden-Baden

Prof. Dr. U. X. Kaisers, Ulm

Prof. Dr. W. Meißner, Jena

Prof. Dr. C. Nau, Lübeck

Dr. M. Rähmer, Mainz

Prof. Dr. A. Schleppers, Nürnberg

Prof. Dr. G. Theilmeier, Hannover

Prof. Dr. M. Thiel, Mannheim

Prof. Dr. F. Wappler, Köln

Prof. Dr. M. Weigand, Heidelberg

Redaktion

Alexandra Hisom M.A. &

Dipl.-Sozw. Holger Sorgatz

Korrespondenzadresse: Roritzerstraße 27 |

90419 Nürnberg | Deutschland

Tel.: 0911 9337812 | Fax: 0911 3938195

E-Mail: anaesth.intensivmed@dgai-ev.de

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |
97500 Ebelsbach | Deutschland
www.aktiv-druck.de

Geschäftsführung

Wolfgang Schröder | Jan Schröder |
Nadja Schwarz
Tel.: 09522 943560 | Fax: 09522 943567
E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Engelhardt
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler
Roritzerstraße 27, 90419 Nürnberg
Tel.: 0171 9432534 | Fax: 0911 3938195
E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Manfred Wuttke | Stefanie Triebert
Tel.: 09522 943571 | Fax: 09522 943577
E-Mail: ai@aktiv-druck.de

Titelbild

Dipl.-Designerin Monique Minde,
Nürnberg

Erscheinungsweise 2018

Der 59. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

- Einzelhefte 30,- €
- Jahresabonnement:
 - Europa (ohne Schweiz) 258,- €
(inkl. 7 % MwSt.)
 - Schweiz 266,- €
 - Rest der Welt 241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

- Europa (ohne Schweiz) 94,- €
(inkl. 7 % MwSt.)
- Schweiz 90,- €
- Rest der Welt 94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem
Impressum auf www.ai-online.info

Indexed in **Current Contents®/Clinical
Medicine, EMBASE/Excerpta Medica;
Medical Documentation Service;
Research Alert; Sci Search; SUBIS
Current Awareness in Biomedicine;
VINITI: Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urhe-
berrechtlich geschützt. Jegliche Art von
Vervielfältigungen – sei es auf mechani-
schem, digitalem oder sonst möglichem
Wege – bleibt vorbehalten. Die Aktiv
Druck & Verlags GmbH ist allein auto-
risiert, Rechte zu vergeben und Sonder-
drucke für gewerbliche Zwecke, gleich
in welcher Sprache, herzustellen. An-
fragen hierzu sind nur an den Verlag zu
richten. Jede im Bereich eines gewerbli-
chen Unternehmens zulässig hergestellte
oder benutzte Kopie dient gewerblichen
Zwecken gem. § 54 (2) UrhG. Die Wie-
dergabe von Gebrauchsnamen, Handels-
namen, Warenbezeichnungen usw. in
dieser Zeitschrift berechtigt auch ohne
besondere Kennzeichnung nicht zu der
Annahme, dass solche Namen im Sinne
der Warenzeichen- und Markenschutz-
Gesetzgebung als frei zu betrachten wä-
ren und daher von jedermann benutzt
werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanwei-
sungen und Applikationsformen kann
vom Verlag und den Herausgebern keine
Gewähr übernommen werden. Derartige
Angaben müssen vom jeweiligen An-
wender im Einzelfall anhand anderer
Literaturstellen auf ihre Richtigkeit über-
prüft werden. Gleiches gilt für berufs-
und verbandspolitische Stellungnahmen
und Empfehlungen.

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

I would like to participate in the project

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Nina Schnabel
Roritzerstrasse 27 | 90419 Nuremberg | Germany
Tel.: +49-911-9337822 | Fax: +49-911-3938195
Email: nschnabel@orphananesthesia.eu